Clinical Trials Update: Aug. 28, 2006
T-Cell Lymphoma Ulcerative Colitis Bipolar Disorders
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
This study will evaluate the safety and effectiveness of pralatrexate when administered with vitamin B12 and folic acid supplements in people with relapsed or refractory peripheral T-cell lymphoma. Volunteers must have relapsed-refractory aggressive non-cutaneous peripheral T-cell lymphoma that recurred after at least one chemotherapy treatment, and must have adequate hematological, hepatic, and renal function. Women must not be or become pregnant while receiving pralatrexate, and men who are not surgically sterile must agree to practice a medically acceptable contraceptive regimen. Other criteria apply.
The research sites are in New York City, Duarte, Calif., and Houston, Texas.
This is a research study of an investigational drug for adults with mild-to-moderate ulcerative colitis currently in remission. Candidates at least 18 may be eligible if ulcerative colitis has been in remission for 1-12 months, if they have never had phenylketonuria, and if they do not have a history of allergy or intolerance to aspirin, mesalamine, or other salicylates.
The research sites are located throughout the United States.
This study will evaluate the effectiveness of aripiprazole in combination with lamotrigine compared with inactive placebo in combination with lamotrigine for people with bipolar I disorder. Volunteers at least 18 who had a manic or mixed episode of sufficient severity to require treatment with a mood stabilizer or antipsychotic may qualify. Volunteers will not be eligible if they've been treated with aripiprazole within past three months or if they are allergic, intolerant, hypersensitive, or refractory to aripiprazole or lamotrigine.
The research sites are located across the United States.
Copyright 2006 Thomson CenterWatch. All rights reserved.